Seattle Genetics Inc. is finally bringing in a late-stage breast cancer candidate, a year after failing to license a different drug, by acquiring local rival Cascadian Therapeutics Inc. and its oral tyrosine kinase inhibitor (TKI) tucatinib, now in a pivotal study for patients with HER2-positive metastatic breast cancer with or without brain metastases.
Last February, Seattle Genetics said it would bolster its portfolio – consisting for now solely of Adcetris (brentuximab vedotin), an...








